<?xml version='1.0' encoding='UTF-8'?>
<uniprot xmlns="http://uniprot.org/uniprot" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://uniprot.org/uniprot http://www.uniprot.org/support/docs/uniprot.xsd">
<entry dataset="Swiss-Prot" created="2004-07-19" modified="2017-09-27" version="154">
<accession>O95278</accession>
<accession>B3KMU5</accession>
<accession>B4DRZ2</accession>
<accession>O95483</accession>
<accession>Q5T3F5</accession>
<accession>Q6IS15</accession>
<accession>Q8IU96</accession>
<accession>Q8IX24</accession>
<accession>Q8IX25</accession>
<accession>Q9BS66</accession>
<accession>Q9UEN2</accession>
<name>EPM2A_HUMAN</name>
<protein>
<recommendedName>
<fullName evidence="42">Laforin</fullName>
<ecNumber evidence="23 36 37 38 39">3.1.3.-</ecNumber>
<ecNumber evidence="55">3.1.3.16</ecNumber>
<ecNumber evidence="6 8">3.1.3.48</ecNumber>
</recommendedName>
<alternativeName>
<fullName evidence="47 49">Glucan phosphatase</fullName>
</alternativeName>
<alternativeName>
<fullName evidence="49 50">Glycogen phosphatase</fullName>
</alternativeName>
<alternativeName>
<fullName>Lafora PTPase</fullName>
<shortName evidence="43">LAFPTPase</shortName>
</alternativeName>
</protein>
<gene>
<name type="primary">EPM2A</name>
</gene>
<organism>
<name type="scientific">Homo sapiens</name>
<name type="common">Human</name>
<dbReference type="NCBI Taxonomy" id="9606"/>
<lineage>
<taxon>Eukaryota</taxon>
<taxon>Metazoa</taxon>
<taxon>Chordata</taxon>
<taxon>Craniata</taxon>
<taxon>Vertebrata</taxon>
<taxon>Euteleostomi</taxon>
<taxon>Mammalia</taxon>
<taxon>Eutheria</taxon>
<taxon>Euarchontoglires</taxon>
<taxon>Primates</taxon>
<taxon>Haplorrhini</taxon>
<taxon>Catarrhini</taxon>
<taxon>Hominidae</taxon>
<taxon>Homo</taxon>
</lineage>
</organism>
<reference key="1">
<citation type="journal article" date="1998" name="Nat. Genet." volume="20" first="171" last="174">
<title>Mutations in a gene encoding a novel protein tyrosine phosphatase cause progressive myoclonus epilepsy.</title>
<authorList>
<person name="Minassian B.A."/>
<person name="Lee J.R."/>
<person name="Herbrick J.-A."/>
<person name="Huizenga J."/>
<person name="Soder S."/>
<person name="Mungall A.J."/>
<person name="Dunham I."/>
<person name="Gardner R."/>
<person name="Fong C.G."/>
<person name="Carpenter S."/>
<person name="Jardim L."/>
<person name="Satishchandra P."/>
<person name="Andermann E."/>
<person name="Snead O.C. III"/>
<person name="Lopes-Cendes I."/>
<person name="Tsui L.-C."/>
<person name="Delgado-Escueta A.V."/>
<person name="Rouleau G.A."/>
<person name="Scherer S.W."/>
</authorList>
<dbReference type="PubMed" id="9771710"/>
<dbReference type="DOI" id="10.1038/2470"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2)</scope>
<scope>ALTERNATIVE SPLICING</scope>
<scope>TISSUE SPECIFICITY</scope>
<scope>VARIANTS EPM2 CYS-108; SER-279 AND LEU-293</scope>
<scope>VARIANT ASP-114</scope>
</reference>
<reference key="2">
<citation type="journal article" date="2000" name="Hum. Mol. Genet." volume="9" first="2251" last="2261">
<title>Laforin, defective in the progressive myoclonus epilepsy of Lafora type, is a dual-specificity phosphatase associated with polyribosomes.</title>
<authorList>
<person name="Ganesh S."/>
<person name="Agarwala K.L."/>
<person name="Ueda K."/>
<person name="Akagi T."/>
<person name="Shoda K."/>
<person name="Usui T."/>
<person name="Hashikawa T."/>
<person name="Osada H."/>
<person name="Delgado-Escueta A.V."/>
<person name="Yamakawa K."/>
</authorList>
<dbReference type="PubMed" id="11001928"/>
<dbReference type="DOI" id="10.1093/oxfordjournals.hmg.a018916"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1)</scope>
<scope>FUNCTIONAL CHARACTERIZATION</scope>
<scope>CATALYTIC ACTIVITY</scope>
<scope>SUBCELLULAR LOCATION</scope>
<scope>CHARACTERIZATION OF VARIANTS EPM2 HIS-171 AND LEU-293</scope>
<source>
<tissue>Fetal brain</tissue>
</source>
</reference>
<reference key="3">
<citation type="submission" date="1998-08" db="EMBL/GenBank/DDBJ databases">
<authorList>
<person name="Lee J.R."/>
<person name="Scherer S.W."/>
</authorList>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1)</scope>
</reference>
<reference key="4">
<citation type="submission" date="2001-11" db="EMBL/GenBank/DDBJ databases">
<title>Cloning of differentially spliced transcripts of the EPM2A gene.</title>
<authorList>
<person name="Ganesh S."/>
<person name="Yamakawa K."/>
</authorList>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 8)</scope>
<scope>NUCLEOTIDE SEQUENCE [MRNA] OF 25-331 (ISOFORM 4)</scope>
<source>
<tissue>Cerebellum</tissue>
<tissue>Fetal brain</tissue>
</source>
</reference>
<reference key="5">
<citation type="journal article" date="2004" name="Nat. Genet." volume="36" first="40" last="45">
<title>Complete sequencing and characterization of 21,243 full-length human cDNAs.</title>
<authorList>
<person name="Ota T."/>
<person name="Suzuki Y."/>
<person name="Nishikawa T."/>
<person name="Otsuki T."/>
<person name="Sugiyama T."/>
<person name="Irie R."/>
<person name="Wakamatsu A."/>
<person name="Hayashi K."/>
<person name="Sato H."/>
<person name="Nagai K."/>
<person name="Kimura K."/>
<person name="Makita H."/>
<person name="Sekine M."/>
<person name="Obayashi M."/>
<person name="Nishi T."/>
<person name="Shibahara T."/>
<person name="Tanaka T."/>
<person name="Ishii S."/>
<person name="Yamamoto J."/>
<person name="Saito K."/>
<person name="Kawai Y."/>
<person name="Isono Y."/>
<person name="Nakamura Y."/>
<person name="Nagahari K."/>
<person name="Murakami K."/>
<person name="Yasuda T."/>
<person name="Iwayanagi T."/>
<person name="Wagatsuma M."/>
<person name="Shiratori A."/>
<person name="Sudo H."/>
<person name="Hosoiri T."/>
<person name="Kaku Y."/>
<person name="Kodaira H."/>
<person name="Kondo H."/>
<person name="Sugawara M."/>
<person name="Takahashi M."/>
<person name="Kanda K."/>
<person name="Yokoi T."/>
<person name="Furuya T."/>
<person name="Kikkawa E."/>
<person name="Omura Y."/>
<person name="Abe K."/>
<person name="Kamihara K."/>
<person name="Katsuta N."/>
<person name="Sato K."/>
<person name="Tanikawa M."/>
<person name="Yamazaki M."/>
<person name="Ninomiya K."/>
<person name="Ishibashi T."/>
<person name="Yamashita H."/>
<person name="Murakawa K."/>
<person name="Fujimori K."/>
<person name="Tanai H."/>
<person name="Kimata M."/>
<person name="Watanabe M."/>
<person name="Hiraoka S."/>
<person name="Chiba Y."/>
<person name="Ishida S."/>
<person name="Ono Y."/>
<person name="Takiguchi S."/>
<person name="Watanabe S."/>
<person name="Yosida M."/>
<person name="Hotuta T."/>
<person name="Kusano J."/>
<person name="Kanehori K."/>
<person name="Takahashi-Fujii A."/>
<person name="Hara H."/>
<person name="Tanase T.-O."/>
<person name="Nomura Y."/>
<person name="Togiya S."/>
<person name="Komai F."/>
<person name="Hara R."/>
<person name="Takeuchi K."/>
<person name="Arita M."/>
<person name="Imose N."/>
<person name="Musashino K."/>
<person name="Yuuki H."/>
<person name="Oshima A."/>
<person name="Sasaki N."/>
<person name="Aotsuka S."/>
<person name="Yoshikawa Y."/>
<person name="Matsunawa H."/>
<person name="Ichihara T."/>
<person name="Shiohata N."/>
<person name="Sano S."/>
<person name="Moriya S."/>
<person name="Momiyama H."/>
<person name="Satoh N."/>
<person name="Takami S."/>
<person name="Terashima Y."/>
<person name="Suzuki O."/>
<person name="Nakagawa S."/>
<person name="Senoh A."/>
<person name="Mizoguchi H."/>
<person name="Goto Y."/>
<person name="Shimizu F."/>
<person name="Wakebe H."/>
<person name="Hishigaki H."/>
<person name="Watanabe T."/>
<person name="Sugiyama A."/>
<person name="Takemoto M."/>
<person name="Kawakami B."/>
<person name="Yamazaki M."/>
<person name="Watanabe K."/>
<person name="Kumagai A."/>
<person name="Itakura S."/>
<person name="Fukuzumi Y."/>
<person name="Fujimori Y."/>
<person name="Komiyama M."/>
<person name="Tashiro H."/>
<person name="Tanigami A."/>
<person name="Fujiwara T."/>
<person name="Ono T."/>
<person name="Yamada K."/>
<person name="Fujii Y."/>
<person name="Ozaki K."/>
<person name="Hirao M."/>
<person name="Ohmori Y."/>
<person name="Kawabata A."/>
<person name="Hikiji T."/>
<person name="Kobatake N."/>
<person name="Inagaki H."/>
<person name="Ikema Y."/>
<person name="Okamoto S."/>
<person name="Okitani R."/>
<person name="Kawakami T."/>
<person name="Noguchi S."/>
<person name="Itoh T."/>
<person name="Shigeta K."/>
<person name="Senba T."/>
<person name="Matsumura K."/>
<person name="Nakajima Y."/>
<person name="Mizuno T."/>
<person name="Morinaga M."/>
<person name="Sasaki M."/>
<person name="Togashi T."/>
<person name="Oyama M."/>
<person name="Hata H."/>
<person name="Watanabe M."/>
<person name="Komatsu T."/>
<person name="Mizushima-Sugano J."/>
<person name="Satoh T."/>
<person name="Shirai Y."/>
<person name="Takahashi Y."/>
<person name="Nakagawa K."/>
<person name="Okumura K."/>
<person name="Nagase T."/>
<person name="Nomura N."/>
<person name="Kikuchi H."/>
<person name="Masuho Y."/>
<person name="Yamashita R."/>
<person name="Nakai K."/>
<person name="Yada T."/>
<person name="Nakamura Y."/>
<person name="Ohara O."/>
<person name="Isogai T."/>
<person name="Sugano S."/>
</authorList>
<dbReference type="PubMed" id="14702039"/>
<dbReference type="DOI" id="10.1038/ng1285"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 7 AND 8)</scope>
<source>
<tissue>Fetal brain</tissue>
<tissue>Teratocarcinoma</tissue>
</source>
</reference>
<reference key="6">
<citation type="journal article" date="2003" name="Nature" volume="425" first="805" last="811">
<title>The DNA sequence and analysis of human chromosome 6.</title>
<authorList>
<person name="Mungall A.J."/>
<person name="Palmer S.A."/>
<person name="Sims S.K."/>
<person name="Edwards C.A."/>
<person name="Ashurst J.L."/>
<person name="Wilming L."/>
<person name="Jones M.C."/>
<person name="Horton R."/>
<person name="Hunt S.E."/>
<person name="Scott C.E."/>
<person name="Gilbert J.G.R."/>
<person name="Clamp M.E."/>
<person name="Bethel G."/>
<person name="Milne S."/>
<person name="Ainscough R."/>
<person name="Almeida J.P."/>
<person name="Ambrose K.D."/>
<person name="Andrews T.D."/>
<person name="Ashwell R.I.S."/>
<person name="Babbage A.K."/>
<person name="Bagguley C.L."/>
<person name="Bailey J."/>
<person name="Banerjee R."/>
<person name="Barker D.J."/>
<person name="Barlow K.F."/>
<person name="Bates K."/>
<person name="Beare D.M."/>
<person name="Beasley H."/>
<person name="Beasley O."/>
<person name="Bird C.P."/>
<person name="Blakey S.E."/>
<person name="Bray-Allen S."/>
<person name="Brook J."/>
<person name="Brown A.J."/>
<person name="Brown J.Y."/>
<person name="Burford D.C."/>
<person name="Burrill W."/>
<person name="Burton J."/>
<person name="Carder C."/>
<person name="Carter N.P."/>
<person name="Chapman J.C."/>
<person name="Clark S.Y."/>
<person name="Clark G."/>
<person name="Clee C.M."/>
<person name="Clegg S."/>
<person name="Cobley V."/>
<person name="Collier R.E."/>
<person name="Collins J.E."/>
<person name="Colman L.K."/>
<person name="Corby N.R."/>
<person name="Coville G.J."/>
<person name="Culley K.M."/>
<person name="Dhami P."/>
<person name="Davies J."/>
<person name="Dunn M."/>
<person name="Earthrowl M.E."/>
<person name="Ellington A.E."/>
<person name="Evans K.A."/>
<person name="Faulkner L."/>
<person name="Francis M.D."/>
<person name="Frankish A."/>
<person name="Frankland J."/>
<person name="French L."/>
<person name="Garner P."/>
<person name="Garnett J."/>
<person name="Ghori M.J."/>
<person name="Gilby L.M."/>
<person name="Gillson C.J."/>
<person name="Glithero R.J."/>
<person name="Grafham D.V."/>
<person name="Grant M."/>
<person name="Gribble S."/>
<person name="Griffiths C."/>
<person name="Griffiths M.N.D."/>
<person name="Hall R."/>
<person name="Halls K.S."/>
<person name="Hammond S."/>
<person name="Harley J.L."/>
<person name="Hart E.A."/>
<person name="Heath P.D."/>
<person name="Heathcott R."/>
<person name="Holmes S.J."/>
<person name="Howden P.J."/>
<person name="Howe K.L."/>
<person name="Howell G.R."/>
<person name="Huckle E."/>
<person name="Humphray S.J."/>
<person name="Humphries M.D."/>
<person name="Hunt A.R."/>
<person name="Johnson C.M."/>
<person name="Joy A.A."/>
<person name="Kay M."/>
<person name="Keenan S.J."/>
<person name="Kimberley A.M."/>
<person name="King A."/>
<person name="Laird G.K."/>
<person name="Langford C."/>
<person name="Lawlor S."/>
<person name="Leongamornlert D.A."/>
<person name="Leversha M."/>
<person name="Lloyd C.R."/>
<person name="Lloyd D.M."/>
<person name="Loveland J.E."/>
<person name="Lovell J."/>
<person name="Martin S."/>
<person name="Mashreghi-Mohammadi M."/>
<person name="Maslen G.L."/>
<person name="Matthews L."/>
<person name="McCann O.T."/>
<person name="McLaren S.J."/>
<person name="McLay K."/>
<person name="McMurray A."/>
<person name="Moore M.J.F."/>
<person name="Mullikin J.C."/>
<person name="Niblett D."/>
<person name="Nickerson T."/>
<person name="Novik K.L."/>
<person name="Oliver K."/>
<person name="Overton-Larty E.K."/>
<person name="Parker A."/>
<person name="Patel R."/>
<person name="Pearce A.V."/>
<person name="Peck A.I."/>
<person name="Phillimore B.J.C.T."/>
<person name="Phillips S."/>
<person name="Plumb R.W."/>
<person name="Porter K.M."/>
<person name="Ramsey Y."/>
<person name="Ranby S.A."/>
<person name="Rice C.M."/>
<person name="Ross M.T."/>
<person name="Searle S.M."/>
<person name="Sehra H.K."/>
<person name="Sheridan E."/>
<person name="Skuce C.D."/>
<person name="Smith S."/>
<person name="Smith M."/>
<person name="Spraggon L."/>
<person name="Squares S.L."/>
<person name="Steward C.A."/>
<person name="Sycamore N."/>
<person name="Tamlyn-Hall G."/>
<person name="Tester J."/>
<person name="Theaker A.J."/>
<person name="Thomas D.W."/>
<person name="Thorpe A."/>
<person name="Tracey A."/>
<person name="Tromans A."/>
<person name="Tubby B."/>
<person name="Wall M."/>
<person name="Wallis J.M."/>
<person name="West A.P."/>
<person name="White S.S."/>
<person name="Whitehead S.L."/>
<person name="Whittaker H."/>
<person name="Wild A."/>
<person name="Willey D.J."/>
<person name="Wilmer T.E."/>
<person name="Wood J.M."/>
<person name="Wray P.W."/>
<person name="Wyatt J.C."/>
<person name="Young L."/>
<person name="Younger R.M."/>
<person name="Bentley D.R."/>
<person name="Coulson A."/>
<person name="Durbin R.M."/>
<person name="Hubbard T."/>
<person name="Sulston J.E."/>
<person name="Dunham I."/>
<person name="Rogers J."/>
<person name="Beck S."/>
</authorList>
<dbReference type="PubMed" id="14574404"/>
<dbReference type="DOI" id="10.1038/nature02055"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]</scope>
</reference>
<reference key="7">
<citation type="submission" date="2005-09" db="EMBL/GenBank/DDBJ databases">
<authorList>
<person name="Mural R.J."/>
<person name="Istrail S."/>
<person name="Sutton G.G."/>
<person name="Florea L."/>
<person name="Halpern A.L."/>
<person name="Mobarry C.M."/>
<person name="Lippert R."/>
<person name="Walenz B."/>
<person name="Shatkay H."/>
<person name="Dew I."/>
<person name="Miller J.R."/>
<person name="Flanigan M.J."/>
<person name="Edwards N.J."/>
<person name="Bolanos R."/>
<person name="Fasulo D."/>
<person name="Halldorsson B.V."/>
<person name="Hannenhalli S."/>
<person name="Turner R."/>
<person name="Yooseph S."/>
<person name="Lu F."/>
<person name="Nusskern D.R."/>
<person name="Shue B.C."/>
<person name="Zheng X.H."/>
<person name="Zhong F."/>
<person name="Delcher A.L."/>
<person name="Huson D.H."/>
<person name="Kravitz S.A."/>
<person name="Mouchard L."/>
<person name="Reinert K."/>
<person name="Remington K.A."/>
<person name="Clark A.G."/>
<person name="Waterman M.S."/>
<person name="Eichler E.E."/>
<person name="Adams M.D."/>
<person name="Hunkapiller M.W."/>
<person name="Myers E.W."/>
<person name="Venter J.C."/>
</authorList>
</citation>
<scope>NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]</scope>
</reference>
<reference key="8">
<citation type="journal article" date="2004" name="Genome Res." volume="14" first="2121" last="2127">
<title>The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).</title>
<authorList>
<consortium name="The MGC Project Team"/>
</authorList>
<dbReference type="PubMed" id="15489334"/>
<dbReference type="DOI" id="10.1101/gr.2596504"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 6)</scope>
<source>
<tissue>Hypothalamus</tissue>
<tissue>Kidney</tissue>
</source>
</reference>
<reference key="9">
<citation type="journal article" date="1999" name="Hum. Mol. Genet." volume="8" first="345" last="352">
<title>A novel protein tyrosine phosphatase gene is mutated in progressive myoclonus epilepsy of the Lafora type (EPM2).</title>
<authorList>
<person name="Serratosa J.M."/>
<person name="Gomez-Garre P."/>
<person name="Gallardo M.E."/>
<person name="Anta B."/>
<person name="de Bernabe D.B."/>
<person name="Lindhout D."/>
<person name="Augustijn P.B."/>
<person name="Tassinari C.A."/>
<person name="Malafosse R.M."/>
<person name="Topcu M."/>
<person name="Grid D."/>
<person name="Dravet C."/>
<person name="Berkovic S.F."/>
<person name="de Cordoba S.R."/>
</authorList>
<dbReference type="PubMed" id="9931343"/>
<dbReference type="DOI" id="10.1093/hmg/8.2.345"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] OF 82-331 (ISOFORMS 1 AND 2)</scope>
<scope>VARIANTS EPM2 HIS-171; ILE-194; SER-279 AND ASN-294</scope>
</reference>
<reference key="10">
<citation type="journal article" date="2001" name="Ann. Neurol." volume="49" first="271" last="275">
<title>Laforin is a cell membrane and endoplasmic reticulum-associated protein tyrosine phosphatase.</title>
<authorList>
<person name="Minassian B.A."/>
<person name="Andrade D.M."/>
<person name="Ianzano L."/>
<person name="Young E.J."/>
<person name="Chan E."/>
<person name="Ackerley C.A."/>
<person name="Scherer S.W."/>
</authorList>
<dbReference type="PubMed" id="11220751"/>
<dbReference type="DOI" id="10.1002/1531-8249(20010201)49:2&lt;271::AID-ANA52>3.3.CO;2-4"/>
</citation>
<scope>FUNCTION</scope>
<scope>CATALYTIC ACTIVITY</scope>
<scope>SUBCELLULAR LOCATION</scope>
<scope>MUTAGENESIS OF CYS-266</scope>
<scope>ACTIVE SITE</scope>
</reference>
<reference key="11">
<citation type="journal article" date="2002" name="Biochem. Biophys. Res. Commun." volume="291" first="1134" last="1137">
<title>Alternative splicing modulates subcellular localization of laforin.</title>
<authorList>
<person name="Ganesh S."/>
<person name="Suzuki T."/>
<person name="Yamakawa K."/>
</authorList>
<dbReference type="PubMed" id="11883934"/>
<dbReference type="DOI" id="10.1006/bbrc.2002.6590"/>
</citation>
<scope>ALTERNATIVE SPLICING</scope>
<scope>SUBCELLULAR LOCATION (ISOFORM 2)</scope>
</reference>
<reference key="12">
<citation type="journal article" date="2002" name="J. Biol. Chem." volume="277" first="2377" last="2380">
<title>A unique carbohydrate binding domain targets the Lafora disease phosphatase to glycogen.</title>
<authorList>
<person name="Wang J."/>
<person name="Stuckey J.A."/>
<person name="Wishart M.J."/>
<person name="Dixon J.E."/>
</authorList>
<dbReference type="PubMed" id="11739371"/>
<dbReference type="DOI" id="10.1074/jbc.C100686200"/>
</citation>
<scope>GLYCOGEN-BINDING</scope>
<scope>DOMAIN</scope>
<scope>SUBCELLULAR LOCATION</scope>
<scope>CHARACTERIZATION OF VARIANT EPM2 GLY-32</scope>
<scope>CATALYTIC ACTIVITY</scope>
<scope>ACTIVE SITE</scope>
<scope>MUTAGENESIS OF LYS-87 AND CYS-266</scope>
</reference>
<reference key="13">
<citation type="journal article" date="2003" name="Genomics" volume="81" first="579" last="587">
<title>Identification of a novel protein interacting with laforin, the EPM2A progressive myoclonus epilepsy gene product.</title>
<authorList>
<person name="Ianzano L."/>
<person name="Zhao X.C."/>
<person name="Minassian B.A."/>
<person name="Scherer S.W."/>
</authorList>
<dbReference type="PubMed" id="12782127"/>
<dbReference type="DOI" id="10.1016/S0888-7543(03)00094-6"/>
</citation>
<scope>INTERACTION WITH EPM2AIP1</scope>
</reference>
<reference key="14">
<citation type="journal article" date="2003" name="Hum. Mol. Genet." volume="12" first="2359" last="2368">
<title>The Lafora disease gene product laforin interacts with HIRIP5, a phylogenetically conserved protein containing a NifU-like domain.</title>
<authorList>
<person name="Ganesh S."/>
<person name="Tsurutani N."/>
<person name="Suzuki T."/>
<person name="Ueda K."/>
<person name="Agarwala K.L."/>
<person name="Osada H."/>
<person name="Delgado-Escueta A.V."/>
<person name="Yamakawa K."/>
</authorList>
<dbReference type="PubMed" id="12915448"/>
<dbReference type="DOI" id="10.1093/hmg/ddg253"/>
</citation>
<scope>INTERACTION WITH HIRIP5</scope>
</reference>
<reference key="15">
<citation type="journal article" date="2003" name="Hum. Mol. Genet." volume="12" first="3161" last="3171">
<title>Laforin, the dual-phosphatase responsible for Lafora disease, interacts with R5 (PTG), a regulatory subunit of protein phosphatase-1 that enhances glycogen accumulation.</title>
<authorList>
<person name="Fernandez-Sanchez M.E."/>
<person name="Criado-Garcia O."/>
<person name="Heath K.E."/>
<person name="Garcia-Fojeda B."/>
<person name="Medrano-Fernandez I."/>
<person name="Gomez-Garre P."/>
<person name="Sanz P."/>
<person name="Serratosa J.M."/>
<person name="Rodriguez de Cordoba S."/>
</authorList>
<dbReference type="PubMed" id="14532330"/>
<dbReference type="DOI" id="10.1093/hmg/ddg340"/>
</citation>
<scope>FUNCTION</scope>
<scope>CATALYTIC ACTIVITY</scope>
<scope>SELF-INTERACTION</scope>
<scope>SUBCELLULAR LOCATION</scope>
<scope>GLYCOGEN-BINDING</scope>
<scope>INTERACTION WITH PPP1R3C</scope>
<scope>TISSUE SPECIFICITY</scope>
<scope>MUTAGENESIS OF ASP-235 AND CYS-266</scope>
<scope>ACTIVE SITE</scope>
<scope>CHARACTERIZATION OF VARIANTS EPM2 GLY-32; LEU-84; CYS-108; ILE-194; SER-240; SER-279; LEU-293; ASN-294 AND LEU-301</scope>
</reference>
<reference key="16">
<citation type="journal article" date="2004" name="Biochem. Biophys. Res. Commun." volume="313" first="1101" last="1109">
<title>The carbohydrate-binding domain of Lafora disease protein targets Lafora polyglucosan bodies.</title>
<authorList>
<person name="Ganesh S."/>
<person name="Tsurutani N."/>
<person name="Suzuki T."/>
<person name="Hoshii Y."/>
<person name="Ishihara T."/>
<person name="Delgado-Escueta A.V."/>
<person name="Yamakawa K."/>
</authorList>
<dbReference type="PubMed" id="14706656"/>
<dbReference type="DOI" id="10.1016/j.bbrc.2003.12.043"/>
</citation>
<scope>BINDING TO GLYCOGEN AND LAFORA BODIES</scope>
<scope>DOMAIN</scope>
<scope>CHARACTERIZATION OF VARIANTS EPM2 PRO-25; LYS-28; GLY-32 AND LEU-88</scope>
<scope>CHARACTERIZATION OF VARIANT PRO-46</scope>
</reference>
<reference key="17">
<citation type="journal article" date="2004" name="Hum. Mol. Genet." volume="13" first="1117" last="1129">
<title>Laforin preferentially binds the neurotoxic starch-like polyglucosans, which form in its absence in progressive myoclonus epilepsy.</title>
<authorList>
<person name="Chan E.M."/>
<person name="Ackerley C.A."/>
<person name="Lohi H."/>
<person name="Ianzano L."/>
<person name="Cortez M.A."/>
<person name="Shannon P."/>
<person name="Scherer S.W."/>
<person name="Minassian B.A."/>
</authorList>
<dbReference type="PubMed" id="15102711"/>
<dbReference type="DOI" id="10.1093/hmg/ddh130"/>
</citation>
<scope>FUNCTION</scope>
<scope>SUBCELLULAR LOCATION</scope>
<scope>BINDING TO LAFORA GLUCAN BODIES</scope>
</reference>
<reference key="18">
<citation type="journal article" date="2005" name="Proc. Natl. Acad. Sci. U.S.A." volume="102" first="8501" last="8506">
<title>Insights into Lafora disease: malin is an E3 ubiquitin ligase that ubiquitinates and promotes the degradation of laforin.</title>
<authorList>
<person name="Gentry M.S."/>
<person name="Worby C.A."/>
<person name="Dixon J.E."/>
</authorList>
<dbReference type="PubMed" id="15930137"/>
<dbReference type="DOI" id="10.1073/pnas.0503285102"/>
</citation>
<scope>INTERACTION WITH NHLRC1</scope>
<scope>POLYUBIQUITINATION</scope>
</reference>
<reference key="19">
<citation type="journal article" date="2006" name="J. Biol. Chem." volume="281" first="30412" last="30418">
<title>Laforin, a dual specificity phosphatase that dephosphorylates complex carbohydrates.</title>
<authorList>
<person name="Worby C.A."/>
<person name="Gentry M.S."/>
<person name="Dixon J.E."/>
</authorList>
<dbReference type="PubMed" id="16901901"/>
<dbReference type="DOI" id="10.1074/jbc.M606117200"/>
</citation>
<scope>FUNCTION AS A GLUCAN PHOSPHATASE</scope>
<scope>CATALYTIC ACTIVITY</scope>
<scope>INTERACTION WITH PPP1R3B; PPP1R3C AND PPP1R3D</scope>
</reference>
<reference key="20">
<citation type="journal article" date="2006" name="J. Biol. Chem." volume="281" first="34768" last="34774">
<title>Dimerization of Laforin is required for its optimal phosphatase activity, regulation of GSK3beta phosphorylation, and Wnt signaling.</title>
<authorList>
<person name="Liu Y."/>
<person name="Wang Y."/>
<person name="Wu C."/>
<person name="Liu Y."/>
<person name="Zheng P."/>
</authorList>
<dbReference type="PubMed" id="16971387"/>
<dbReference type="DOI" id="10.1074/jbc.M607778200"/>
</citation>
<scope>FUNCTION</scope>
<scope>CATALYTIC ACTIVITY</scope>
<scope>SUBUNIT</scope>
</reference>
<reference key="21">
<citation type="journal article" date="2007" name="Genes Dev." volume="21" first="2399" last="2409">
<title>A role for AGL ubiquitination in the glycogen storage disorders of Lafora and Cori's disease.</title>
<authorList>
<person name="Cheng A."/>
<person name="Zhang M."/>
<person name="Gentry M.S."/>
<person name="Worby C.A."/>
<person name="Dixon J.E."/>
<person name="Saltiel A.R."/>
</authorList>
<dbReference type="PubMed" id="17908927"/>
<dbReference type="DOI" id="10.1101/gad.1553207"/>
</citation>
<scope>SUBCELLULAR LOCATION</scope>
</reference>
<reference key="22">
<citation type="journal article" date="2008" name="Hum. Mol. Genet." volume="17" first="3010" last="3020">
<title>Modulation of functional properties of laforin phosphatase by alternative splicing reveals a novel mechanism for the EPM2A gene in Lafora progressive myoclonus epilepsy.</title>
<authorList>
<person name="Dubey D."/>
<person name="Ganesh S."/>
</authorList>
<dbReference type="PubMed" id="18617530"/>
<dbReference type="DOI" id="10.1093/hmg/ddn199"/>
</citation>
<scope>FUNCTION (ISOFORMS 1 AND 2)</scope>
<scope>CATALYTIC ACTIVITY</scope>
<scope>HOMODIMERIZATION</scope>
<scope>SUBUNIT</scope>
<scope>SUBCELLULAR LOCATION</scope>
<scope>INTERACTION WITH NHLRC1 AND GLYCOGEN</scope>
</reference>
<reference key="23">
<citation type="journal article" date="2008" name="J. Biol. Chem." volume="283" first="4069" last="4076">
<title>Malin decreases glycogen accumulation by promoting the degradation of protein targeting to glycogen (PTG).</title>
<authorList>
<person name="Worby C.A."/>
<person name="Gentry M.S."/>
<person name="Dixon J.E."/>
</authorList>
<dbReference type="PubMed" id="18070875"/>
<dbReference type="DOI" id="10.1074/jbc.M708712200"/>
</citation>
<scope>FUNCTION</scope>
<scope>INTERACTION WITH PPP1R3C</scope>
</reference>
<reference key="24">
<citation type="journal article" date="2009" name="Hum. Mol. Genet." volume="18" first="688" last="700">
<title>The malin-laforin complex suppresses the cellular toxicity of misfolded proteins by promoting their degradation through the ubiquitin-proteasome system.</title>
<authorList>
<person name="Garyali P."/>
<person name="Siwach P."/>
<person name="Singh P.K."/>
<person name="Puri R."/>
<person name="Mittal S."/>
<person name="Sengupta S."/>
<person name="Parihar R."/>
<person name="Ganesh S."/>
</authorList>
<dbReference type="PubMed" id="19036738"/>
<dbReference type="DOI" id="10.1093/hmg/ddn398"/>
</citation>
<scope>FUNCTION</scope>
<scope>COMPLEX FORMATION WITH NHLRC1 AND HSP70</scope>
</reference>
<reference key="25">
<citation type="journal article" date="2009" name="J. Biol. Chem." volume="284" first="22657" last="22663">
<title>Hyperphosphorylation and aggregation of Tau in laforin-deficient mice, an animal model for Lafora disease.</title>
<authorList>
<person name="Puri R."/>
<person name="Suzuki T."/>
<person name="Yamakawa K."/>
<person name="Ganesh S."/>
</authorList>
<dbReference type="PubMed" id="19542233"/>
<dbReference type="DOI" id="10.1074/jbc.M109.009688"/>
</citation>
<scope>INTERACTION WITH MAPT</scope>
</reference>
<reference key="26">
<citation type="journal article" date="2010" name="Hum. Mol. Genet." volume="19" first="2867" last="2876">
<title>Laforin, the most common protein mutated in Lafora disease, regulates autophagy.</title>
<authorList>
<person name="Aguado C."/>
<person name="Sarkar S."/>
<person name="Korolchuk V.I."/>
<person name="Criado O."/>
<person name="Vernia S."/>
<person name="Boya P."/>
<person name="Sanz P."/>
<person name="de Cordoba S.R."/>
<person name="Knecht E."/>
<person name="Rubinsztein D.C."/>
</authorList>
<dbReference type="PubMed" id="20453062"/>
<dbReference type="DOI" id="10.1093/hmg/ddq190"/>
</citation>
<scope>FUNCTION</scope>
</reference>
<reference key="27">
<citation type="journal article" date="2011" name="Biochem. J." volume="439" first="265" last="275">
<title>Laforin, a dual-specificity phosphatase involved in Lafora disease, is phosphorylated at Ser25 by AMP-activated protein kinase.</title>
<authorList>
<person name="Roma-Mateo C."/>
<person name="Solaz-Fuster Mdel C."/>
<person name="Gimeno-Alcaniz J.V."/>
<person name="Dukhande V.V."/>
<person name="Donderis J."/>
<person name="Worby C.A."/>
<person name="Marina A."/>
<person name="Criado O."/>
<person name="Koller A."/>
<person name="Rodriguez De Cordoba S."/>
<person name="Gentry M.S."/>
<person name="Sanz P."/>
</authorList>
<dbReference type="PubMed" id="21728993"/>
<dbReference type="DOI" id="10.1042/BJ20110150"/>
</citation>
<scope>PHOSPHORYLATION AT SER-25</scope>
<scope>MUTAGENESIS OF SER-25; SER-168; THR-187 AND THR-194</scope>
<scope>INTERACTION WITH NHLRC1; PPP1R3C AND PRKAA2</scope>
</reference>
<reference key="28">
<citation type="journal article" date="2012" name="Brain" volume="135" first="2684" last="2698">
<title>Early-onset Lafora body disease.</title>
<authorList>
<person name="Turnbull J."/>
<person name="Girard J.M."/>
<person name="Lohi H."/>
<person name="Chan E.M."/>
<person name="Wang P."/>
<person name="Tiberia E."/>
<person name="Omer S."/>
<person name="Ahmed M."/>
<person name="Bennett C."/>
<person name="Chakrabarty A."/>
<person name="Tyagi A."/>
<person name="Liu Y."/>
<person name="Pencea N."/>
<person name="Zhao X."/>
<person name="Scherer S.W."/>
<person name="Ackerley C.A."/>
<person name="Minassian B.A."/>
</authorList>
<dbReference type="PubMed" id="22961547"/>
<dbReference type="DOI" id="10.1093/brain/aws205"/>
</citation>
<scope>INTERACTION WITH PRDM8</scope>
</reference>
<reference key="29">
<citation type="journal article" date="2012" name="Genomics" volume="99" first="36" last="43">
<title>Identification and characterization of novel splice variants of the human EPM2A gene mutated in Lafora progressive myoclonus epilepsy.</title>
<authorList>
<person name="Dubey D."/>
<person name="Parihar R."/>
<person name="Ganesh S."/>
</authorList>
<dbReference type="PubMed" id="22036712"/>
<dbReference type="DOI" id="10.1016/j.ygeno.2011.10.001"/>
</citation>
<scope>ALTERNATIVE SPLICING (ISOFORMS 4; 5; 6; 7 AND 9)</scope>
<scope>FUNCTION (ISOFORMS 2 AND 7)</scope>
<scope>INTERACTION WITH NHLRC1 AND GLYCOGEN</scope>
<scope>SUBCELLULAR LOCATION</scope>
<scope>SUBUNIT</scope>
<scope>CATALYTIC ACTIVITY</scope>
<scope>MUTAGENESIS OF CYS-266</scope>
<scope>ACTIVE SITE</scope>
</reference>
<reference key="30">
<citation type="journal article" date="2013" name="Int. J. Biochem. Cell Biol." volume="45" first="1479" last="1488">
<title>Glycogenic activity of R6, a protein phosphatase 1 regulatory subunit, is modulated by the laforin-malin complex.</title>
<authorList>
<person name="Rubio-Villena C."/>
<person name="Garcia-Gimeno M.A."/>
<person name="Sanz P."/>
</authorList>
<dbReference type="PubMed" id="23624058"/>
<dbReference type="DOI" id="10.1016/j.biocel.2013.04.019"/>
</citation>
<scope>FUNCTION</scope>
<scope>INTERACTION WITH PPP1R3D</scope>
</reference>
<reference key="31">
<citation type="journal article" date="2013" name="PLoS ONE" volume="8" first="E69523" last="E69523">
<title>Dimerization of the glucan phosphatase laforin requires the participation of cysteine 329.</title>
<authorList>
<person name="Sanchez-Martin P."/>
<person name="Raththagala M."/>
<person name="Bridges T.M."/>
<person name="Husodo S."/>
<person name="Gentry M.S."/>
<person name="Sanz P."/>
<person name="Roma-Mateo C."/>
</authorList>
<dbReference type="PubMed" id="23922729"/>
<dbReference type="DOI" id="10.1371/journal.pone.0069523"/>
</citation>
<scope>CATALYTIC ACTIVITY</scope>
<scope>FUNCTION</scope>
<scope>INTERACTION WITH NHLRC1</scope>
<scope>SUBUNIT</scope>
<scope>MUTAGENESIS OF 109-CYS-CYS-110; CYS-123; CYS-169; CYS-205; CYS-250; CYS-266; CYS-329 AND 329-CYS--CYS-331</scope>
</reference>
<reference key="32">
<citation type="journal article" date="2015" name="J. Biol. Chem." volume="290" first="23361" last="23370">
<title>Mechanistic insights into glucan phosphatase activity against polyglucan substrates.</title>
<authorList>
<person name="Meekins D.A."/>
<person name="Raththagala M."/>
<person name="Auger K.D."/>
<person name="Turner B.D."/>
<person name="Santelia D."/>
<person name="Koetting O."/>
<person name="Gentry M.S."/>
<person name="Vander Kooi C.W."/>
</authorList>
<dbReference type="PubMed" id="26231210"/>
<dbReference type="DOI" id="10.1074/jbc.M115.658203"/>
</citation>
<scope>CATALYTIC ACTIVITY</scope>
<scope>FUNCTION</scope>
<scope>MOTIF</scope>
<scope>CHARACTERIZATION OF VARIANT EPM2 GLY-32</scope>
</reference>
<reference key="33" evidence="1">
<citation type="journal article" date="2015" name="J. Biol. Chem." volume="290" first="4552" last="4559">
<title>Dimeric quaternary structure of human laforin.</title>
<authorList>
<person name="Sankhala R.S."/>
<person name="Koksal A.C."/>
<person name="Ho L."/>
<person name="Nitschke F."/>
<person name="Minassian B.A."/>
<person name="Cingolani G."/>
</authorList>
<dbReference type="PubMed" id="25538239"/>
<dbReference type="DOI" id="10.1074/jbc.M114.627406"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 148-331</scope>
<scope>FUNCTION AS GLUCAN PHOSPHATASE</scope>
<scope>CATALYTIC ACTIVITY</scope>
<scope>SUBUNIT</scope>
<scope>MUTAGENESIS OF CYS-169; ARG-171; ASP-197; ASP-235; CYS-266; ARG-272 AND CYS-329</scope>
</reference>
<reference key="34" evidence="2">
<citation type="journal article" date="2015" name="Mol. Cell" volume="57" first="261" last="272">
<title>Structural mechanism of laforin function in glycogen dephosphorylation and lafora disease.</title>
<authorList>
<person name="Raththagala M."/>
<person name="Brewer M.K."/>
<person name="Parker M.W."/>
<person name="Sherwood A.R."/>
<person name="Wong B.K."/>
<person name="Hsu S."/>
<person name="Bridges T.M."/>
<person name="Paasch B.C."/>
<person name="Hellman L.M."/>
<person name="Husodo S."/>
<person name="Meekins D.A."/>
<person name="Taylor A.O."/>
<person name="Turner B.D."/>
<person name="Auger K.D."/>
<person name="Dukhande V.V."/>
<person name="Chakravarthy S."/>
<person name="Sanz P."/>
<person name="Woods V.L. Jr."/>
<person name="Li S."/>
<person name="Vander Kooi C.W."/>
<person name="Gentry M.S."/>
</authorList>
<dbReference type="PubMed" id="25544560"/>
<dbReference type="DOI" id="10.1016/j.molcel.2014.11.020"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS) OF 1-329 IN COMPLEX WITH MALTOHEXAOSE AND PHOSPHATE</scope>
<scope>CATALYTIC ACTIVITY</scope>
<scope>FUNCTION</scope>
<scope>SUBUNIT</scope>
<scope>MUTAGENESIS OF VAL-8; LYS-87; TRP-99; ILE-126; THR-142; ASP-197; MET-236 AND CYS-266</scope>
<scope>CHARACTERIZATION OF VARIANTS EPM2 GLY-32; HIS-171; SER-240; ASN-294 AND LEU-301</scope>
</reference>
<reference key="35">
<citation type="journal article" date="2000" name="Eur. J. Hum. Genet." volume="8" first="946" last="954">
<title>Mutational spectrum of the EPM2A gene in progressive myoclonus epilepsy of Lafora: high degree of allelic heterogeneity and prevalence of deletions.</title>
<authorList>
<person name="Gomez-Garre P."/>
<person name="Sanz Y."/>
<person name="Rodriguez de Cordoba S.R."/>
<person name="Serratosa J.M."/>
</authorList>
<dbReference type="PubMed" id="11175283"/>
<dbReference type="DOI" id="10.1038/sj.ejhg.5200571"/>
</citation>
<scope>VARIANTS EPM2 LEU-84; SER-240 AND LEU-301</scope>
</reference>
<reference key="36">
<citation type="journal article" date="2001" name="Mol. Cell. Probes" volume="15" first="281" last="289">
<title>Mutation screening for Japanese Lafora's disease patients: identification of novel sequence variants in the coding and upstream regulatory regions of EPM2A gene.</title>
<authorList>
<person name="Ganesh S."/>
<person name="Shoda K."/>
<person name="Amano K."/>
<person name="Uchiyama A."/>
<person name="Kumada S."/>
<person name="Moriyama N."/>
<person name="Hirose S."/>
<person name="Yamakawa K."/>
</authorList>
<dbReference type="PubMed" id="11735300"/>
<dbReference type="DOI" id="10.1006/mcpr.2001.0371"/>
</citation>
<scope>VARIANT PRO-46</scope>
</reference>
<reference key="37">
<citation type="journal article" date="2002" name="Hum. Mol. Genet." volume="11" first="1263" last="1271">
<title>Genotype-phenotype correlations for EPM2A mutations in Lafora's progressive myoclonus epilepsy: exon 1 mutations associate with an early-onset cognitive deficit subphenotype.</title>
<authorList>
<person name="Ganesh S."/>
<person name="Delgado-Escueta A.V."/>
<person name="Suzuki T."/>
<person name="Francheschetti S."/>
<person name="Riggio C."/>
<person name="Avanzini G."/>
<person name="Rabinowicz A."/>
<person name="Bohlega S."/>
<person name="Bailey J."/>
<person name="Alonso M.E."/>
<person name="Rasmussen A."/>
<person name="Thomson A.E."/>
<person name="Ochoa A."/>
<person name="Prado A.J."/>
<person name="Medina M.T."/>
<person name="Yamakawa K."/>
</authorList>
<dbReference type="PubMed" id="12019207"/>
<dbReference type="DOI" id="10.1093/hmg/11.11.1263"/>
</citation>
<scope>VARIANTS EPM2 PRO-25; CYS-108; HIS-171 AND LEU-293</scope>
<scope>CHARACTERIZATION OF VARIANTS EPM2 GLY-32; CYS-108; ILE-194; SER-279 AND ASN-294</scope>
</reference>
<reference key="38">
<citation type="journal article" date="2003" name="J. Hum. Genet." volume="48" first="51" last="54">
<title>Two novel mutations in the EPM2A gene in a Korean patient with Lafora's progressive myoclonus epilepsy.</title>
<authorList>
<person name="Ki C.S."/>
<person name="Kong S.Y."/>
<person name="Seo D.W."/>
<person name="Hong S.B."/>
<person name="Kim H.J."/>
<person name="Kim J.W."/>
</authorList>
<dbReference type="PubMed" id="12560877"/>
<dbReference type="DOI" id="10.1007/s100380300006"/>
</citation>
<scope>VARIANT EPM2 ALA-187</scope>
</reference>
<reference key="39">
<citation type="journal article" date="2004" name="Epilepsia" volume="45" first="294" last="295">
<title>A novel exon 1 mutation in a patient with atypical Lafora progressive myoclonus epilepsy seen as childhood-onset cognitive deficit.</title>
<authorList>
<person name="Annesi G."/>
<person name="Sofia V."/>
<person name="Gambardella A."/>
<person name="Ciro Candiano I.C."/>
<person name="Spadafora P."/>
<person name="Annesi F."/>
<person name="Cutuli N."/>
<person name="De Marco E.V."/>
<person name="Civitelli D."/>
<person name="Carrideo S."/>
<person name="Tarantino P."/>
<person name="Barone R."/>
<person name="Zappia M."/>
<person name="Quattrone A."/>
</authorList>
<dbReference type="PubMed" id="15009235"/>
<dbReference type="DOI" id="10.1111/j.0013-9580.2004.33203.x"/>
</citation>
<scope>VARIANT EPM2 PRO-91</scope>
</reference>
<reference key="40">
<citation type="journal article" date="2004" name="Hum. Mutat." volume="23" first="170" last="176">
<title>Loss of function of the cytoplasmic isoform of the protein laforin (EPM2A) causes Lafora progressive myoclonus epilepsy.</title>
<authorList>
<person name="Ianzano L."/>
<person name="Young E.J."/>
<person name="Zhao X.C."/>
<person name="Chan E.M."/>
<person name="Rodriguez M.T."/>
<person name="Torrado M.V."/>
<person name="Scherer S.W."/>
<person name="Minassian B.A."/>
</authorList>
<dbReference type="PubMed" id="14722920"/>
<dbReference type="DOI" id="10.1002/humu.10306"/>
</citation>
<scope>VARIANTS EPM2 PRO-91; HIS-171 AND SER-279</scope>
<scope>CATALYTIC ACTIVITY</scope>
<scope>SUBCELLULAR LOCATION</scope>
</reference>
<reference key="41">
<citation type="journal article" date="2005" name="J. Hum. Genet." volume="50" first="347" last="352">
<title>Mutations in the NHLRC1 gene are the common cause for Lafora disease in the Japanese population.</title>
<authorList>
<person name="Singh S."/>
<person name="Suzuki T."/>
<person name="Uchiyama A."/>
<person name="Kumada S."/>
<person name="Moriyama N."/>
<person name="Hirose S."/>
<person name="Takahashi Y."/>
<person name="Sugie H."/>
<person name="Mizoguchi K."/>
<person name="Inoue Y."/>
<person name="Kimura K."/>
<person name="Sawaishi Y."/>
<person name="Yamakawa K."/>
<person name="Ganesh S."/>
</authorList>
<dbReference type="PubMed" id="16021330"/>
<dbReference type="DOI" id="10.1007/s10038-005-0263-7"/>
</citation>
<scope>VARIANT PRO-46</scope>
</reference>
<reference key="42">
<citation type="journal article" date="2008" name="Hum. Mutat." volume="29" first="E1" last="12">
<title>Lafora disease in the Indian population: EPM2A and NHLRC1 gene mutations and their impact on subcellular localization of laforin and malin.</title>
<authorList>
<person name="Singh S."/>
<person name="Satishchandra P."/>
<person name="Shankar S.K."/>
<person name="Ganesh S."/>
</authorList>
<dbReference type="PubMed" id="18311786"/>
<dbReference type="DOI" id="10.1002/humu.20737"/>
</citation>
<scope>VARIANTS EPM2 ASN-140; TYR-148; LYS-210 AND TRP-310</scope>
<scope>CHARACTERIZATION OF VARIANT EPM2 TRP-310</scope>
<scope>SUBCELLULAR LOCATION</scope>
</reference>
<comment type="function">
<text evidence="3 6 8 10 16 18 23 24 26 28 29 31 33 35 36 37 38 39">Plays an important role in preventing glycogen hyperphosphorylation and the formation of insoluble aggregates, via its activity as glycogen phosphatase, and by promoting the ubiquitination of proteins involved in glycogen metabolism via its interaction with the E3 ubiquitin ligase NHLRC1/malin. Shows strong phosphatase activity towards complex carbohydrates in vitro, avoiding glycogen hyperphosphorylation which is associated with reduced branching and formation of insoluble aggregates (PubMed:16901901, PubMed:23922729, PubMed:26231210, PubMed:25538239, PubMed:25544560). Dephosphorylates phosphotyrosine and synthetic substrates, such as para-nitrophenylphosphate (pNPP), and has low activity with phosphoserine and phosphothreonine substrates (in vitro) (PubMed:11001928, PubMed:11220751, PubMed:11739371, PubMed:14532330, PubMed:16971387, PubMed:18617530, PubMed:22036712, PubMed:23922729, PubMed:14722920). Has been shown to dephosphorylate MAPT (By similarity). Forms a complex with NHLRC1/malin and HSP70, which suppresses the cellular toxicity of misfolded proteins by promoting their degradation through the ubiquitin-proteasome system (UPS). Acts as a scaffold protein to facilitate PPP1R3C/PTG ubiquitination by NHLRC1/malin (PubMed:23922729). Also promotes proteasome-independent protein degradation through the macroautophagy pathway (PubMed:20453062).</text>
</comment>
<comment type="function">
<text evidence="28 33">Isoform 2: does not bind to glycogen (PubMed:18617530). Lacks phosphatase activity and might function as a dominant-negative regulator for the phosphatase activity of isoform 1 and isoform 7 (PubMed:18617530, PubMed:22036712).</text>
</comment>
<comment type="function">
<text evidence="33">Isoform 7: has phosphatase activity (in vitro).</text>
</comment>
<comment type="catalytic activity">
<text evidence="5 6 8">Protein tyrosine phosphate + H(2)O = protein tyrosine + phosphate.</text>
</comment>
<comment type="catalytic activity">
<text evidence="55">[a protein]-serine/threonine phosphate + H(2)O = [a protein]-serine/threonine + phosphate.</text>
</comment>
<comment type="subunit">
<text evidence="10 14 15 16 17 20 21 23 24 26 28 30 33 34 35 36 37 38">Homodimer (PubMed:16971387, PubMed:18617530, PubMed:23922729, PubMed:25538239, PubMed:25544560). Interacts with itself (PubMed:14532330). Interacts with PPP1R3B, PPP1R3C, PPP1R3D, HIRIP5, and EPM2AIP1 (PubMed:12782127, PubMed:12915448, PubMed:14532330, PubMed:16901901, PubMed:18070875). Binds glycogen and Lafora bodies (PubMed:11739371, PubMed:14532330, PubMed:14706656, PubMed:15102711, PubMed:18617530, PubMed:22036712). Interacts with NHLRC1/malin (via the NHL repeats) (PubMed:15930137, PubMed:22036712, PubMed:23922729). Forms a complex with NHLRC1/malin and HSP70 (PubMed:19036738). Interacts with PPP1R3D; in the presence of NHLC1/malin the interaction leads to ubiquitination and autophagic degradation of PPP1R3D. Interacts (via the phosphatase domain) with MAPT/Tau; the interaction dephosphorylates MAPT (PubMed:19542233). Isoform 1 and isoform 2 interact to form a heterodimeric complex that lacks phosphatase activity (in vitro) (PubMed:18617530). Active phosphatase isoform 7 and isoform 1 interact with each other, but give rise to lower phosphatase activity than isoform 1 or isoform 7 by themselves (in vitro) (PubMed:22036712). Active phosphatase isoform 7 and inactive isoform 2 interact with each other, but give rise to lower phosphatase activity than isoform 7 by itself (in vitro) (PubMed:22036712). Interacts with PRDM8 (PubMed:22961547).</text>
</comment>
<comment type="interaction">
<interactant intactId="EBI-2506661"/>
<interactant intactId="EBI-6426628">
<id>Q6VVB1</id>
<label>NHLRC1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>7</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-2506661"/>
<interactant intactId="EBI-2506727">
<id>Q9UQK1</id>
<label>PPP1R3C</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>5</experiments>
</comment>
<comment type="subcellular location">
<subcellularLocation>
<location evidence="6 8 10 20 25">Cytoplasm</location>
</subcellularLocation>
<text evidence="25">Under glycogenolytic conditions localizes to the nucleus.</text>
</comment>
<comment type="subcellular location">
<molecule>Isoform 1</molecule>
<subcellularLocation>
<location evidence="6 10 11 16 27 28 33">Cytoplasm</location>
</subcellularLocation>
<subcellularLocation>
<location evidence="6 18 27">Endoplasmic reticulum membrane</location>
<topology evidence="6 27">Peripheral membrane protein</topology>
<orientation evidence="6 27">Cytoplasmic side</orientation>
</subcellularLocation>
<subcellularLocation>
<location evidence="8">Cell membrane</location>
</subcellularLocation>
<text evidence="6 8 10 11 16 27">Colocalizes with glycogen synthase in punctate structures in the cytoplasm (PubMed:11739371, PubMed:14532330). Primarily associated with polyribosomes at the rough endoplasmic reticulum, and also detected at the plasma membrane (PubMed:11001928, PubMed:11220751, PubMed:11883934, PubMed:18311786).</text>
</comment>
<comment type="subcellular location">
<molecule>Isoform 2</molecule>
<subcellularLocation>
<location evidence="28">Cytoplasm</location>
</subcellularLocation>
<subcellularLocation>
<location evidence="11">Endoplasmic reticulum membrane</location>
<topology evidence="11">Peripheral membrane protein</topology>
<orientation evidence="11">Cytoplasmic side</orientation>
</subcellularLocation>
<subcellularLocation>
<location evidence="11">Cell membrane</location>
</subcellularLocation>
<subcellularLocation>
<location evidence="11 18 28">Nucleus</location>
</subcellularLocation>
<text evidence="11 28">Also found in the nucleus.</text>
</comment>
<comment type="subcellular location">
<molecule>Isoform 4</molecule>
<subcellularLocation>
<location evidence="33">Cytoplasm</location>
</subcellularLocation>
<subcellularLocation>
<location evidence="33">Nucleus</location>
</subcellularLocation>
</comment>
<comment type="subcellular location">
<molecule>Isoform 5</molecule>
<subcellularLocation>
<location evidence="33">Cytoplasm</location>
</subcellularLocation>
<subcellularLocation>
<location evidence="33">Nucleus</location>
</subcellularLocation>
</comment>
<comment type="subcellular location">
<molecule>Isoform 7</molecule>
<subcellularLocation>
<location evidence="33">Cytoplasm</location>
</subcellularLocation>
</comment>
<comment type="alternative products">
<event type="alternative splicing"/>
<event type="alternative initiation"/>
<isoform>
<id>O95278-1</id>
<name>1</name>
<name>A</name>
<name evidence="44">LDH1</name>
<name evidence="48">Laf331</name>
<sequence type="displayed"/>
</isoform>
<isoform>
<id>O95278-2</id>
<name>2</name>
<name>B</name>
<name>C-terISO</name>
<name evidence="48">Laf317</name>
<sequence type="described" ref="VSP_011017 VSP_011018"/>
<text>Produced by alternative splicing.</text>
</isoform>
<isoform>
<id>O95278-4</id>
<name>4</name>
<name evidence="48">Laf152</name>
<sequence type="described" ref="VSP_011015 VSP_011016"/>
<text>Produced by alternative splicing. May be due to an intron retention.</text>
</isoform>
<isoform>
<id>O95278-5</id>
<name>5</name>
<name evidence="48">Laf224</name>
<sequence type="described" ref="VSP_042496 VSP_042497"/>
<text>Produced by alternative splicing.</text>
</isoform>
<isoform>
<id>O95278-6</id>
<name>6</name>
<name evidence="48">Laf88</name>
<sequence type="described" ref="VSP_042494"/>
<text evidence="33">Produced by alternative initiation at Met-244 of isoform 1. Transcript amplified but protein not detected.</text>
</isoform>
<isoform>
<id>O95278-7</id>
<name>7</name>
<name evidence="48">Laf177</name>
<sequence type="described" ref="VSP_042495"/>
<text evidence="33">Produced by alternative splicing. Active phosphatase.</text>
</isoform>
<isoform>
<id>O95278-8</id>
<name>8</name>
<sequence type="described" ref="VSP_042493"/>
<text>Produced by alternative splicing. No experimental confirmation available.</text>
</isoform>
<isoform>
<id>B3EWF7-1</id>
<name>9</name>
<name evidence="48">POCR</name>
<sequence type="external"/>
<text>Produced by alternative initiation. Arises due to the use of an alternative initiation codon in exon 1 out of frame with isoform 1 and results in a completely different isoform.</text>
</isoform>
</comment>
<comment type="tissue specificity">
<text evidence="16 40">Expressed in heart, skeletal muscle, kidney, pancreas and brain. Isoform 4 is also expressed in the placenta.</text>
</comment>
<comment type="domain">
<text evidence="10 17">The CBM20 domain mediates binding to cytoplasmic glycogen and to Lafora polyglucosan bodies.</text>
</comment>
<comment type="PTM">
<text evidence="21">Polyubiquitinated by NHLRC1/malin.</text>
</comment>
<comment type="PTM">
<text evidence="32">Phosphorylation on Ser-25 by AMPK affects the phosphatase activity of the enzyme and its ability to homodimerize and interact with NHLRC1, PPP1R3C or PRKAA2.</text>
</comment>
<comment type="disease" evidence="6 7 10 12 13 16 17 18 19 27 38 39 40 41">
<disease id="DI-00954">
<name>Epilepsy, progressive myoclonic 2</name>
<acronym>EPM2</acronym>
<description>An autosomal recessive and severe form of adolescent-onset progressive epilepsy. Typically, as seizures increase in frequency, cognitive function declines towards dementia, and affected individuals die usually within 10 years after onset. EPM2 occurs worldwide, but it is particularly common in the mediterranean countries of southern Europe and northern Africa, in southern India and in the Middle East. At the cellular level, it is characterized by accumulation of starch-like polyglucosans called Lafora bodies (LBs) that are most abundant in organs with the highest glucose metabolism: brain, heart, liver and skeletal muscle. Among other conditions involving polyglucosans, EPM2 is unique in that the inclusions are in neuronal dendrites but not axons and the forming polyglucosan fibrils are associated with the endoplasmic reticulum.</description>
<dbReference type="MIM" id="254780"/>
</disease>
<text>The disease is caused by mutations affecting the gene represented in this entry.</text>
</comment>
<comment type="similarity">
<text evidence="54">Belongs to the protein-tyrosine phosphatase family.</text>
</comment>
<comment type="sequence caution" evidence="54">
<conflict type="miscellaneous discrepancy">
<sequence resource="EMBL-CDS" id="AAO15523" version="1"/>
</conflict>
<text>Probable cloning artifact.</text>
</comment>
<comment type="sequence caution" evidence="54">
<conflict type="frameshift">
<sequence resource="EMBL-CDS" id="BAG51107" version="1"/>
</conflict>
<location>
<position position="223"/>
</location>
</comment>
<comment type="online information" name="The Lafora progressive myoclonus epilepsy mutation and polymorphism database">
<link uri="http://projects.tcag.ca/lafora/"/>
</comment>
<dbReference type="EC" id="3.1.3.-" evidence="23 36 37 38 39"/>
<dbReference type="EC" id="3.1.3.16" evidence="55"/>
<dbReference type="EC" id="3.1.3.48" evidence="6 8"/>
<dbReference type="EMBL" id="AF084535">
<property type="protein sequence ID" value="AAC83347.2"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="AF284580">
<property type="protein sequence ID" value="AAG18377.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="AF454491">
<property type="protein sequence ID" value="AAO15523.1"/>
<property type="status" value="ALT_SEQ"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="AF454492">
<property type="protein sequence ID" value="AAO15524.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="AF454493">
<property type="protein sequence ID" value="AAO15525.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="AF454494">
<property type="protein sequence ID" value="AAO15526.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="AK022721">
<property type="protein sequence ID" value="BAG51107.1"/>
<property type="status" value="ALT_FRAME"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="AK299497">
<property type="protein sequence ID" value="BAG61454.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="AL023806">
<property type="protein sequence ID" value="CAI21419.1"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="AL365193">
<property type="protein sequence ID" value="CAI21419.1"/>
<property type="status" value="JOINED"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="AL365193">
<property type="protein sequence ID" value="CAI21675.1"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="AL023806">
<property type="protein sequence ID" value="CAI21675.1"/>
<property type="status" value="JOINED"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="CH471051">
<property type="protein sequence ID" value="EAW47844.1"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="BC005286">
<property type="protein sequence ID" value="AAH05286.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="BC070047">
<property type="protein sequence ID" value="AAH70047.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="AJ130763">
<property type="protein sequence ID" value="CAA10199.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="AJ130764">
<property type="protein sequence ID" value="CAA10200.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="CCDS" id="CCDS5206.1">
<molecule id="O95278-1"/>
</dbReference>
<dbReference type="RefSeq" id="NP_001018051.1">
<molecule id="O95278-2"/>
<property type="nucleotide sequence ID" value="NM_001018041.1"/>
</dbReference>
<dbReference type="RefSeq" id="NP_005661.1">
<molecule id="O95278-1"/>
<property type="nucleotide sequence ID" value="NM_005670.3"/>
</dbReference>
<dbReference type="RefSeq" id="XP_006715627.1">
<molecule id="O95278-5"/>
<property type="nucleotide sequence ID" value="XM_006715564.3"/>
</dbReference>
<dbReference type="RefSeq" id="XP_011534418.1">
<molecule id="O95278-8"/>
<property type="nucleotide sequence ID" value="XM_011536116.1"/>
</dbReference>
<dbReference type="RefSeq" id="XP_016866789.1">
<molecule id="O95278-7"/>
<property type="nucleotide sequence ID" value="XM_017011300.1"/>
</dbReference>
<dbReference type="RefSeq" id="XP_016866790.1">
<molecule id="O95278-7"/>
<property type="nucleotide sequence ID" value="XM_017011301.1"/>
</dbReference>
<dbReference type="RefSeq" id="XP_016866791.1">
<molecule id="O95278-7"/>
<property type="nucleotide sequence ID" value="XM_017011302.1"/>
</dbReference>
<dbReference type="UniGene" id="Hs.486696"/>
<dbReference type="PDB" id="4R30">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.30"/>
<property type="chains" value="A/B/C/D=148-331"/>
</dbReference>
<dbReference type="PDB" id="4RKK">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.40"/>
<property type="chains" value="A/C=1-329"/>
</dbReference>
<dbReference type="PDBsum" id="4R30"/>
<dbReference type="PDBsum" id="4RKK"/>
<dbReference type="ProteinModelPortal" id="O95278"/>
<dbReference type="SMR" id="O95278"/>
<dbReference type="BioGrid" id="113679">
<property type="interactions" value="23"/>
</dbReference>
<dbReference type="IntAct" id="O95278">
<property type="interactions" value="5"/>
</dbReference>
<dbReference type="STRING" id="9606.ENSP00000356489"/>
<dbReference type="BindingDB" id="O95278"/>
<dbReference type="ChEMBL" id="CHEMBL2311242"/>
<dbReference type="CAZy" id="CBM20">
<property type="family name" value="Carbohydrate-Binding Module Family 20"/>
</dbReference>
<dbReference type="DEPOD" id="O95278"/>
<dbReference type="iPTMnet" id="O95278"/>
<dbReference type="PhosphoSitePlus" id="O95278"/>
<dbReference type="BioMuta" id="RNF213"/>
<dbReference type="PaxDb" id="O95278"/>
<dbReference type="PeptideAtlas" id="O95278"/>
<dbReference type="PRIDE" id="O95278"/>
<dbReference type="DNASU" id="7957"/>
<dbReference type="Ensembl" id="ENST00000367519">
<molecule id="O95278-1"/>
<property type="protein sequence ID" value="ENSP00000356489"/>
<property type="gene ID" value="ENSG00000112425"/>
</dbReference>
<dbReference type="Ensembl" id="ENST00000435470">
<molecule id="O95278-2"/>
<property type="protein sequence ID" value="ENSP00000405913"/>
<property type="gene ID" value="ENSG00000112425"/>
</dbReference>
<dbReference type="Ensembl" id="ENST00000611340">
<molecule id="O95278-8"/>
<property type="protein sequence ID" value="ENSP00000480268"/>
<property type="gene ID" value="ENSG00000112425"/>
</dbReference>
<dbReference type="Ensembl" id="ENST00000618445">
<molecule id="O95278-2"/>
<property type="protein sequence ID" value="ENSP00000480339"/>
<property type="gene ID" value="ENSG00000112425"/>
</dbReference>
<dbReference type="Ensembl" id="ENST00000638262">
<molecule id="O95278-5"/>
<property type="protein sequence ID" value="ENSP00000492876"/>
<property type="gene ID" value="ENSG00000112425"/>
</dbReference>
<dbReference type="Ensembl" id="ENST00000638778">
<molecule id="O95278-8"/>
<property type="protein sequence ID" value="ENSP00000491353"/>
<property type="gene ID" value="ENSG00000112425"/>
</dbReference>
<dbReference type="Ensembl" id="ENST00000638783">
<molecule id="O95278-8"/>
<property type="protein sequence ID" value="ENSP00000491338"/>
<property type="gene ID" value="ENSG00000112425"/>
</dbReference>
<dbReference type="Ensembl" id="ENST00000639423">
<molecule id="O95278-8"/>
<property type="protein sequence ID" value="ENSP00000492701"/>
<property type="gene ID" value="ENSG00000112425"/>
</dbReference>
<dbReference type="Ensembl" id="ENST00000639465">
<molecule id="O95278-8"/>
<property type="protein sequence ID" value="ENSP00000491180"/>
<property type="gene ID" value="ENSG00000112425"/>
</dbReference>
<dbReference type="GeneID" id="7957"/>
<dbReference type="KEGG" id="hsa:7957"/>
<dbReference type="UCSC" id="uc003qkw.4">
<molecule id="O95278-1"/>
<property type="organism name" value="human"/>
</dbReference>
<dbReference type="CTD" id="7957"/>
<dbReference type="DisGeNET" id="7957"/>
<dbReference type="EuPathDB" id="HostDB:ENSG00000112425.13"/>
<dbReference type="GeneCards" id="EPM2A"/>
<dbReference type="GeneReviews" id="EPM2A"/>
<dbReference type="HGNC" id="HGNC:3413">
<property type="gene designation" value="EPM2A"/>
</dbReference>
<dbReference type="HPA" id="HPA053643"/>
<dbReference type="HPA" id="HPA055468"/>
<dbReference type="MalaCards" id="EPM2A"/>
<dbReference type="MIM" id="254780">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="MIM" id="607566">
<property type="type" value="gene"/>
</dbReference>
<dbReference type="neXtProt" id="NX_O95278"/>
<dbReference type="OpenTargets" id="ENSG00000112425"/>
<dbReference type="Orphanet" id="501">
<property type="disease" value="Lafora disease"/>
</dbReference>
<dbReference type="PharmGKB" id="PA27832"/>
<dbReference type="eggNOG" id="KOG1716">
<property type="taxonomic scope" value="Eukaryota"/>
</dbReference>
<dbReference type="eggNOG" id="COG2453">
<property type="taxonomic scope" value="LUCA"/>
</dbReference>
<dbReference type="GeneTree" id="ENSGT00390000010101"/>
<dbReference type="HOGENOM" id="HOG000285975"/>
<dbReference type="HOVERGEN" id="HBG051493"/>
<dbReference type="KO" id="K14165"/>
<dbReference type="OMA" id="GHTDEMK"/>
<dbReference type="OrthoDB" id="EOG091G0GBM"/>
<dbReference type="PhylomeDB" id="O95278"/>
<dbReference type="TreeFam" id="TF332841"/>
<dbReference type="BRENDA" id="3.1.3.16">
<property type="organism ID" value="2681"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-3322077">
<property type="pathway name" value="Glycogen synthesis"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-3785653">
<property type="pathway name" value="Myoclonic epilepsy of Lafora"/>
</dbReference>
<dbReference type="SIGNOR" id="O95278"/>
<dbReference type="ChiTaRS" id="EPM2A">
<property type="organism name" value="human"/>
</dbReference>
<dbReference type="GenomeRNAi" id="7957"/>
<dbReference type="Proteomes" id="UP000005640">
<property type="component" value="Chromosome 6"/>
</dbReference>
<dbReference type="Bgee" id="ENSG00000112425"/>
<dbReference type="CleanEx" id="HS_EPM2A"/>
<dbReference type="ExpressionAtlas" id="O95278">
<property type="expression patterns" value="baseline and differential"/>
</dbReference>
<dbReference type="Genevisible" id="O95278">
<property type="organism ID" value="HS"/>
</dbReference>
<dbReference type="GO" id="GO:0005737">
<property type="term" value="C:cytoplasm"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0098556">
<property type="term" value="C:cytoplasmic side of rough endoplasmic reticulum membrane"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0005829">
<property type="term" value="C:cytosol"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0005654">
<property type="term" value="C:nucleoplasm"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="HPA"/>
</dbReference>
<dbReference type="GO" id="GO:0005634">
<property type="term" value="C:nucleus"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0005886">
<property type="term" value="C:plasma membrane"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="UniProtKB-SubCell"/>
</dbReference>
<dbReference type="GO" id="GO:0030246">
<property type="term" value="F:carbohydrate binding"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0019203">
<property type="term" value="F:carbohydrate phosphatase activity"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:2001069">
<property type="term" value="F:glycogen binding"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0016791">
<property type="term" value="F:phosphatase activity"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0046983">
<property type="term" value="F:protein dimerization activity"/>
<property type="evidence" value="ECO:0000353"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0042803">
<property type="term" value="F:protein homodimerization activity"/>
<property type="evidence" value="ECO:0000353"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0004722">
<property type="term" value="F:protein serine/threonine phosphatase activity"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0004725">
<property type="term" value="F:protein tyrosine phosphatase activity"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0008138">
<property type="term" value="F:protein tyrosine/serine/threonine phosphatase activity"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="InterPro"/>
</dbReference>
<dbReference type="GO" id="GO:2001070">
<property type="term" value="F:starch binding"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="InterPro"/>
</dbReference>
<dbReference type="GO" id="GO:0006914">
<property type="term" value="P:autophagy"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="UniProtKB-KW"/>
</dbReference>
<dbReference type="GO" id="GO:0016311">
<property type="term" value="P:dephosphorylation"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0005978">
<property type="term" value="P:glycogen biosynthetic process"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0005977">
<property type="term" value="P:glycogen metabolic process"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0046959">
<property type="term" value="P:habituation"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0035305">
<property type="term" value="P:negative regulation of dephosphorylation"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0010923">
<property type="term" value="P:negative regulation of phosphatase activity"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0007399">
<property type="term" value="P:nervous system development"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0035335">
<property type="term" value="P:peptidyl-tyrosine dephosphorylation"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0046838">
<property type="term" value="P:phosphorylated carbohydrate dephosphorylation"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0016239">
<property type="term" value="P:positive regulation of macroautophagy"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0006470">
<property type="term" value="P:protein dephosphorylation"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="CDD" id="cd05806">
<property type="entry name" value="CBM20_laforin"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="Gene3D" id="2.60.40.10">
<property type="match status" value="1"/>
</dbReference>
<dbReference type="Gene3D" id="3.90.190.10">
<property type="match status" value="1"/>
</dbReference>
<dbReference type="InterPro" id="IPR013784">
<property type="entry name" value="Carb-bd-like_fold"/>
</dbReference>
<dbReference type="InterPro" id="IPR034831">
<property type="entry name" value="CBM20_laforin"/>
</dbReference>
<dbReference type="InterPro" id="IPR002044">
<property type="entry name" value="CBM_fam20"/>
</dbReference>
<dbReference type="InterPro" id="IPR000340">
<property type="entry name" value="Dual-sp_phosphatase_cat-dom"/>
</dbReference>
<dbReference type="InterPro" id="IPR024950">
<property type="entry name" value="DUSP"/>
</dbReference>
<dbReference type="InterPro" id="IPR013783">
<property type="entry name" value="Ig-like_fold"/>
</dbReference>
<dbReference type="InterPro" id="IPR029021">
<property type="entry name" value="Prot-tyrosine_phosphatase-like"/>
</dbReference>
<dbReference type="InterPro" id="IPR016130">
<property type="entry name" value="Tyr_Pase_AS"/>
</dbReference>
<dbReference type="InterPro" id="IPR000387">
<property type="entry name" value="TYR_PHOSPHATASE_dom"/>
</dbReference>
<dbReference type="InterPro" id="IPR020422">
<property type="entry name" value="TYR_PHOSPHATASE_DUAL_dom"/>
</dbReference>
<dbReference type="PANTHER" id="PTHR10159">
<property type="entry name" value="PTHR10159"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="Pfam" id="PF00686">
<property type="entry name" value="CBM_20"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="Pfam" id="PF00782">
<property type="entry name" value="DSPc"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="SMART" id="SM01065">
<property type="entry name" value="CBM_2"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="SMART" id="SM00195">
<property type="entry name" value="DSPc"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="SUPFAM" id="SSF49452">
<property type="entry name" value="SSF49452"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="SUPFAM" id="SSF52799">
<property type="entry name" value="SSF52799"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PROSITE" id="PS51166">
<property type="entry name" value="CBM20"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PROSITE" id="PS00383">
<property type="entry name" value="TYR_PHOSPHATASE_1"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PROSITE" id="PS50056">
<property type="entry name" value="TYR_PHOSPHATASE_2"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PROSITE" id="PS50054">
<property type="entry name" value="TYR_PHOSPHATASE_DUAL"/>
<property type="match status" value="1"/>
</dbReference>
<proteinExistence type="evidence at protein level"/>
<keyword id="KW-0002">3D-structure</keyword>
<keyword id="KW-0024">Alternative initiation</keyword>
<keyword id="KW-0025">Alternative splicing</keyword>
<keyword id="KW-0072">Autophagy</keyword>
<keyword id="KW-0119">Carbohydrate metabolism</keyword>
<keyword id="KW-1003">Cell membrane</keyword>
<keyword id="KW-0181">Complete proteome</keyword>
<keyword id="KW-0963">Cytoplasm</keyword>
<keyword id="KW-0225">Disease mutation</keyword>
<keyword id="KW-0256">Endoplasmic reticulum</keyword>
<keyword id="KW-0887">Epilepsy</keyword>
<keyword id="KW-0321">Glycogen metabolism</keyword>
<keyword id="KW-0322">Glycogen storage disease</keyword>
<keyword id="KW-0378">Hydrolase</keyword>
<keyword id="KW-0472">Membrane</keyword>
<keyword id="KW-0539">Nucleus</keyword>
<keyword id="KW-0597">Phosphoprotein</keyword>
<keyword id="KW-0621">Polymorphism</keyword>
<keyword id="KW-0904">Protein phosphatase</keyword>
<keyword id="KW-1185">Reference proteome</keyword>
<keyword id="KW-0832">Ubl conjugation</keyword>
<feature type="chain" description="Laforin" id="PRO_0000094838">
<location>
<begin position="1"/>
<end position="331"/>
</location>
</feature>
<feature type="domain" description="CBM20" evidence="4">
<location>
<begin position="1"/>
<end position="124"/>
</location>
</feature>
<feature type="domain" description="Tyrosine-protein phosphatase">
<location>
<begin position="243"/>
<end position="311"/>
</location>
</feature>
<feature type="region of interest" description="Substrate binding" evidence="2 38">
<location>
<begin position="103"/>
<end position="107"/>
</location>
</feature>
<feature type="region of interest" description="Substrate binding" evidence="2 38">
<location>
<begin position="267"/>
<end position="272"/>
</location>
</feature>
<feature type="short sequence motif" description="Glucan phosphatase signature motif CXAGXGR" evidence="61 62">
<location>
<begin position="266"/>
<end position="272"/>
</location>
</feature>
<feature type="active site" description="Phosphocysteine intermediate" evidence="5 56 57 58 59 60 61">
<location>
<position position="266"/>
</location>
</feature>
<feature type="binding site" description="Substrate" evidence="2 38">
<location>
<position position="32"/>
</location>
</feature>
<feature type="binding site" description="Substrate" evidence="2 38">
<location>
<position position="87"/>
</location>
</feature>
<feature type="binding site" description="Substrate" evidence="2 38">
<location>
<position position="197"/>
</location>
</feature>
<feature type="binding site" description="Substrate" evidence="2 38">
<location>
<position position="235"/>
</location>
</feature>
<feature type="binding site" description="Substrate" evidence="2 38">
<location>
<position position="241"/>
</location>
</feature>
<feature type="binding site" description="Substrate" evidence="2 38">
<location>
<position position="304"/>
</location>
</feature>
<feature type="site" description="Required for homodimerization" evidence="36">
<location>
<position position="329"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine; by AMPK" evidence="32">
<location>
<position position="25"/>
</location>
</feature>
<feature type="splice variant" description="In isoform 6." id="VSP_042494" evidence="46">
<location>
<begin position="1"/>
<end position="243"/>
</location>
</feature>
<feature type="splice variant" description="In isoform 7." id="VSP_042495" evidence="45">
<original>MRFRFGVVVPPAVAGARPELLVVGSRPELGRWEPRGAVRLRPAGTAAGDGALALQEPGLWLGEVELAAEEAAQDGAEPGRVDTFWYKFLKREPGGELSWEGNGPHHDRCCTYNENNLVDGVYCLPIGHWIEATGHTNEMKHTTDFYFNIAGHQAMHYSR</original>
<variation>MIFNK</variation>
<location>
<begin position="1"/>
<end position="159"/>
</location>
</feature>
<feature type="splice variant" description="In isoform 8." id="VSP_042493" evidence="45 53">
<location>
<begin position="1"/>
<end position="138"/>
</location>
</feature>
<feature type="splice variant" description="In isoform 4." id="VSP_011015" evidence="53">
<original>NGPHHDRCCTYNENNLVDGVYCLPIGHWIEATGHTNEMKHTTDFYFNIAGHQAMHYSRILPNIWLGSCPRQVEHVTIKLKHELGITAVMNFQTEWDIV</original>
<variation>IASRRLPPAQSGSSGPHPQPGPRPRAGPAGPGGARPGLFARVPAHSPGDLG</variation>
<location>
<begin position="102"/>
<end position="199"/>
</location>
</feature>
<feature type="splice variant" description="In isoform 5." id="VSP_042496" evidence="54">
<location>
<begin position="160"/>
<end position="293"/>
</location>
</feature>
<feature type="splice variant" description="In isoform 4." id="VSP_011016" evidence="53">
<location>
<begin position="200"/>
<end position="331"/>
</location>
</feature>
<feature type="splice variant" description="In isoform 5." id="VSP_042497" evidence="54">
<original>YFLMAKRPAVYIDEEALARAQEDFFQKFGKVRSSVCSL</original>
<variation>PSTDAAPGGVPAACAAGEGTHRVRALQRWGGPLHRGCLRLAPVCDGLESEEGAVFPHGQEAGCLH</variation>
<location>
<begin position="294"/>
<end position="331"/>
</location>
</feature>
<feature type="splice variant" description="In isoform 2." id="VSP_011017" evidence="51 52">
<original>LARAQEDFFQK</original>
<variation>ASQDTFPL</variation>
<location>
<begin position="310"/>
<end position="320"/>
</location>
</feature>
<feature type="splice variant" description="In isoform 2." id="VSP_011018" evidence="51 52">
<location>
<begin position="321"/>
<end position="331"/>
</location>
</feature>
<feature type="sequence variant" description="In EPM2; atypical form; does not affect glycogen binding." id="VAR_019465" evidence="12 17">
<original>S</original>
<variation>P</variation>
<location>
<position position="25"/>
</location>
</feature>
<feature type="sequence variant" description="In EPM2; does not affect glycogen binding." id="VAR_019466" evidence="17">
<original>E</original>
<variation>K</variation>
<location>
<position position="28"/>
</location>
</feature>
<feature type="sequence variant" description="In EPM2; impairs protein stability; affects phosphatase activity; abolishes glycogen binding; abolishes phosphatase activity with insoluble glucan; disrupts the interaction with PPP1R3C; dbSNP:rs104893955." id="VAR_019467" evidence="10 12 16 17 38 39">
<original>W</original>
<variation>G</variation>
<location>
<position position="32"/>
</location>
</feature>
<feature type="sequence variant" description="Does not affect glycogen binding; dbSNP:rs374338349." id="VAR_019468" evidence="9 17 22">
<original>A</original>
<variation>P</variation>
<location>
<position position="46"/>
</location>
</feature>
<feature type="sequence variant" description="In EPM2; affects phosphatase activity and glycogen binding; disrupts the interaction with PPP1R3C." id="VAR_019469" evidence="7 16">
<original>F</original>
<variation>L</variation>
<location>
<position position="84"/>
</location>
</feature>
<feature type="sequence variant" description="In EPM2; does not affect glycogen binding." id="VAR_019470" evidence="17">
<original>F</original>
<variation>L</variation>
<location>
<position position="88"/>
</location>
</feature>
<feature type="sequence variant" description="In EPM2; atypical form; learning difficuties with childhood-onset." id="VAR_019471" evidence="18 19">
<original>R</original>
<variation>P</variation>
<location>
<position position="91"/>
</location>
</feature>
<feature type="sequence variant" description="In EPM2; loss of phosphatase activity; reduced self-interaction capacity; disrupts the interaction with PPP1R3C; dbSNP:rs137852915." id="VAR_019472" evidence="12 16 40">
<original>R</original>
<variation>C</variation>
<location>
<position position="108"/>
</location>
</feature>
<feature type="sequence variant" id="VAR_019473" evidence="40">
<original>E</original>
<variation>D</variation>
<location>
<position position="114"/>
</location>
</feature>
<feature type="sequence variant" description="In EPM2." id="VAR_046383" evidence="27">
<original>K</original>
<variation>N</variation>
<location>
<position position="140"/>
</location>
</feature>
<feature type="sequence variant" description="In EPM2." id="VAR_046384" evidence="27">
<original>N</original>
<variation>Y</variation>
<location>
<position position="148"/>
</location>
</feature>
<feature type="sequence variant" description="In EPM2; results in ubiquitin-positive perinuclear aggregates; no effect on glycogen binding; abolishes phosphatase activity; may affect proper folding; dbSNP:rs137852916." id="VAR_019474" evidence="6 12 18 38 41">
<original>R</original>
<variation>H</variation>
<location>
<position position="171"/>
</location>
</feature>
<feature type="sequence variant" description="In EPM2; abolishes interaction with NHLRC1." id="VAR_019475" evidence="13">
<original>T</original>
<variation>A</variation>
<location>
<position position="187"/>
</location>
</feature>
<feature type="sequence variant" description="In EPM2; results in ubiquitin-positive perinuclear aggregates; loss of phosphatase activity; affects glycogen binding; reduced self-interaction capacity; abolishes interaction with NHLRC1, PPP1R3C and PRKAA2; no effect on phosphorylation of protein; dbSNP:rs375544596." id="VAR_019476" evidence="12 16 41">
<original>T</original>
<variation>I</variation>
<location>
<position position="194"/>
</location>
</feature>
<feature type="sequence variant" description="In EPM2." id="VAR_046385" evidence="27">
<original>E</original>
<variation>K</variation>
<location>
<position position="210"/>
</location>
</feature>
<feature type="sequence variant" description="In EPM2; impaired phosphatase activity; does not affect glycogen binding; disrupts the interaction with PPP1R3C." id="VAR_019477" evidence="7 16 38">
<original>G</original>
<variation>S</variation>
<location>
<position position="240"/>
</location>
</feature>
<feature type="sequence variant" description="In EPM2; results in ubiquitin-positive perinuclear aggregates; loss of phosphatase activity; affects glycogen binding; disrupts the interaction with PPP1R3C; dbSNP:rs137852917." id="VAR_019478" evidence="12 16 18 40 41">
<original>G</original>
<variation>S</variation>
<location>
<position position="279"/>
</location>
</feature>
<feature type="sequence variant" description="In EPM2; results in ubiquitin-positive perinuclear aggregates; may affect proper folding; loss of phosphatase activity; affects glycogen binding; disrupts the interaction with PPP1R3C; dbSNP:rs796052427." id="VAR_019479" evidence="6 12 16 40">
<original>Q</original>
<variation>L</variation>
<location>
<position position="293"/>
</location>
</feature>
<feature type="sequence variant" description="In EPM2; results in ubiquitin-positive perinuclear aggregates; impairs phosphatase activity; affects glycogen binding; disrupts the interaction with PPP1R3C." id="VAR_019480" evidence="12 16 38 41">
<original>Y</original>
<variation>N</variation>
<location>
<position position="294"/>
</location>
</feature>
<feature type="sequence variant" description="In EPM2; impairs protein stability; impairs phosphatase activity; affects glycogen binding; disrupts the interaction with PPP1R3C; dbSNP:rs796052428." id="VAR_019481" evidence="7 16 38">
<original>P</original>
<variation>L</variation>
<location>
<position position="301"/>
</location>
</feature>
<feature type="sequence variant" description="In EPM2; causes location of isoform 1 at cytoplasmic punctae; does not affect homodimerization of isoform 1 but prevents heterodimerization of isoform 1 and isoform 2." id="VAR_046386" evidence="27">
<original>L</original>
<variation>W</variation>
<location>
<position position="310"/>
</location>
</feature>
<feature type="mutagenesis site" description="Loss of phosphatase activity. No effect on glycogen binding." evidence="38">
<original>V</original>
<variation>A</variation>
<location>
<position position="8"/>
</location>
</feature>
<feature type="mutagenesis site" description="Partial loss of phosphatase activity. Abolishes homodimerization. Abolishes interaction with NHLRC1, PPP1R3C and PRKAA2. Does not affect glycogen binding. Reduces stability of the protein." evidence="32">
<original>S</original>
<variation>A</variation>
<location>
<position position="25"/>
</location>
</feature>
<feature type="mutagenesis site" description="Partial loss of phosphatase activity. Increases interaction with NHLRC1. Does not affect interaction with NHLRC1, PPP1R3C or PRKAA2. Does not affect binding to carbohydrate. Does not affect homodimerization." evidence="32">
<original>S</original>
<variation>D</variation>
<location>
<position position="25"/>
</location>
</feature>
<feature type="mutagenesis site" description="Loss of phosphatase activity. Abolishes glycogen binding." evidence="10 38">
<original>K</original>
<variation>A</variation>
<location>
<position position="87"/>
</location>
</feature>
<feature type="mutagenesis site" description="Strongly reduces phosphatase activity. Strongly reduces glycogen binding." evidence="38">
<original>W</original>
<variation>A</variation>
<location>
<position position="99"/>
</location>
</feature>
<feature type="mutagenesis site" description="No effect on homodimerization or carbohydrate binding. Decreased phosphatase activity." evidence="36">
<original>CC</original>
<variation>SS</variation>
<location>
<begin position="109"/>
<end position="110"/>
</location>
</feature>
<feature type="mutagenesis site" description="No effect on homodimerization or carbohydrate binding. Decreased phosphatase activity." evidence="36">
<original>C</original>
<variation>S</variation>
<location>
<position position="123"/>
</location>
</feature>
<feature type="mutagenesis site" description="Strongly decreased phosphatase activity. No effect on glycogen binding." evidence="38">
<original>I</original>
<variation>T</variation>
<location>
<position position="126"/>
</location>
</feature>
<feature type="mutagenesis site" description="Strongly decreased phosphatase activity. No effect on glycogen binding." evidence="38">
<original>T</original>
<variation>A</variation>
<location>
<position position="142"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abolishes interaction with NHLRC1." evidence="32">
<original>S</original>
<variation>A</variation>
<variation>D</variation>
<location>
<position position="168"/>
</location>
</feature>
<feature type="mutagenesis site" description="No effect on homodimerization or carbohydrate binding. Decreased phosphatase activity." evidence="36">
<original>C</original>
<variation>S</variation>
<location>
<position position="169"/>
</location>
</feature>
<feature type="mutagenesis site" description="No effect on phosphatase activity." evidence="37">
<original>C</original>
<variation>S</variation>
<location>
<position position="169"/>
</location>
</feature>
<feature type="mutagenesis site" description="No effect on phosphatase activity." evidence="37">
<original>R</original>
<variation>A</variation>
<location>
<position position="171"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abolishes interaction with NHLRC1." evidence="32">
<original>T</original>
<variation>D</variation>
<location>
<position position="187"/>
</location>
</feature>
<feature type="mutagenesis site" description="Does not affect interaction with NHLRC1, PPP1R3C or PRKAA2." evidence="32">
<original>T</original>
<variation>D</variation>
<location>
<position position="194"/>
</location>
</feature>
<feature type="mutagenesis site" description="Strongly decreased phosphatase activity. No effect on glycogen binding." evidence="37 38">
<original>D</original>
<variation>A</variation>
<location>
<position position="197"/>
</location>
</feature>
<feature type="mutagenesis site" description="No effect on homodimerization or carbohydrate binding. Decreased phosphatase activity." evidence="36">
<original>C</original>
<variation>S</variation>
<location>
<position position="205"/>
</location>
</feature>
<feature type="mutagenesis site" description="Complete loss of phosphatase activity. Does not affect glycogen binding." evidence="16 37">
<original>D</original>
<variation>A</variation>
<location>
<position position="235"/>
</location>
</feature>
<feature type="mutagenesis site" description="Complete loss of phosphatase activity. No effect on glycogen binding." evidence="38">
<original>M</original>
<variation>A</variation>
<location>
<position position="236"/>
</location>
</feature>
<feature type="mutagenesis site" description="No effect on homodimerization or carbohydrate binding. Decreased phosphatase activity." evidence="36">
<original>C</original>
<variation>S</variation>
<location>
<position position="250"/>
</location>
</feature>
<feature type="mutagenesis site" description="Impairs protein stability. Strongly reduces phosphatase activity. No effect on glycogen binding." evidence="38">
<original>L</original>
<variation>A</variation>
<location>
<position position="251"/>
</location>
</feature>
<feature type="mutagenesis site" description="Complete loss of phosphatase activity. Does not affect glycogen binding. Does not affect self-interaction. Increases the interaction with PPP1R3C." evidence="8 10 16 33 36 37 38">
<original>C</original>
<variation>S</variation>
<location>
<position position="266"/>
</location>
</feature>
<feature type="mutagenesis site" description="Complete loss of phosphatase activity." evidence="37">
<original>R</original>
<variation>A</variation>
<location>
<position position="272"/>
</location>
</feature>
<feature type="mutagenesis site" description="Impairs protein stability. Strongly reduces phosphatase activity. No effect on glycogen binding." evidence="38">
<original>F</original>
<variation>S</variation>
<location>
<position position="321"/>
</location>
</feature>
<feature type="mutagenesis site" description="Fails to homodimerize. Does not affect carbohydrate binding or phosphatase activity." evidence="36">
<location>
<begin position="329"/>
<end position="331"/>
</location>
</feature>
<feature type="mutagenesis site" description="Fails to homodimerize. Does not affect carbohydrate binding, interaction with NHLRC1, phosphatase activity, or ubiquitination by NHLRC1." evidence="36">
<original>C</original>
<variation>S</variation>
<location>
<position position="329"/>
</location>
</feature>
<feature type="mutagenesis site" description="No effect on homodimerization." evidence="37">
<original>C</original>
<variation>S</variation>
<location>
<position position="329"/>
</location>
</feature>
<feature type="sequence conflict" description="In Ref. 8; AAH70047." ref="8" evidence="54">
<original>Q</original>
<variation>K</variation>
<location>
<position position="193"/>
</location>
</feature>
<feature type="sequence conflict" description="In Ref. 4; AAO15523." ref="4" evidence="54">
<original>A</original>
<variation>P</variation>
<location>
<position position="248"/>
</location>
</feature>
<feature type="sequence conflict" description="In Ref. 5; BAG61454." ref="5" evidence="54">
<original>K</original>
<variation>E</variation>
<location>
<position position="258"/>
</location>
</feature>
<feature type="sequence conflict" description="In Ref. 5; BAG61454." ref="5" evidence="54">
<original>Y</original>
<variation>H</variation>
<location>
<position position="294"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="1"/>
<end position="9"/>
</location>
</feature>
<feature type="helix" evidence="2">
<location>
<begin position="11"/>
<end position="14"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="19"/>
<end position="26"/>
</location>
</feature>
<feature type="helix" evidence="2">
<location>
<begin position="27"/>
<end position="29"/>
</location>
</feature>
<feature type="turn" evidence="2">
<location>
<begin position="30"/>
<end position="32"/>
</location>
</feature>
<feature type="helix" evidence="2">
<location>
<begin position="34"/>
<end position="36"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="58"/>
<end position="67"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="84"/>
<end position="91"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="97"/>
<end position="103"/>
</location>
</feature>
<feature type="helix" evidence="2">
<location>
<begin position="104"/>
<end position="106"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="108"/>
<end position="110"/>
</location>
</feature>
<feature type="helix" evidence="2">
<location>
<begin position="114"/>
<end position="116"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="121"/>
<end position="123"/>
</location>
</feature>
<feature type="helix" evidence="2">
<location>
<begin position="138"/>
<end position="151"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="157"/>
<end position="161"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="164"/>
<end position="167"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="173"/>
<end position="177"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="178"/>
<end position="183"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="188"/>
<end position="191"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="195"/>
<end position="201"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="203"/>
<end position="205"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="208"/>
<end position="210"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="214"/>
<end position="223"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="227"/>
<end position="230"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="238"/>
<end position="258"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="262"/>
<end position="265"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="271"/>
<end position="283"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="289"/>
<end position="296"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="303"/>
<end position="305"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="307"/>
<end position="321"/>
</location>
</feature>
<evidence key="1" type="ECO:0000244">
<source>
<dbReference type="PDB" id="4R30"/>
</source>
</evidence>
<evidence key="2" type="ECO:0000244">
<source>
<dbReference type="PDB" id="4RKK"/>
</source>
</evidence>
<evidence key="3" type="ECO:0000250">
<source>
<dbReference type="UniProtKB" id="Q9WUA5"/>
</source>
</evidence>
<evidence key="4" type="ECO:0000255">
<source>
<dbReference type="PROSITE-ProRule" id="PRU00594"/>
</source>
</evidence>
<evidence key="5" type="ECO:0000255">
<source>
<dbReference type="PROSITE-ProRule" id="PRU10044"/>
</source>
</evidence>
<evidence key="6" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11001928"/>
</source>
</evidence>
<evidence key="7" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11175283"/>
</source>
</evidence>
<evidence key="8" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11220751"/>
</source>
</evidence>
<evidence key="9" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11735300"/>
</source>
</evidence>
<evidence key="10" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11739371"/>
</source>
</evidence>
<evidence key="11" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11883934"/>
</source>
</evidence>
<evidence key="12" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12019207"/>
</source>
</evidence>
<evidence key="13" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12560877"/>
</source>
</evidence>
<evidence key="14" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12782127"/>
</source>
</evidence>
<evidence key="15" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12915448"/>
</source>
</evidence>
<evidence key="16" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="14532330"/>
</source>
</evidence>
<evidence key="17" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="14706656"/>
</source>
</evidence>
<evidence key="18" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="14722920"/>
</source>
</evidence>
<evidence key="19" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15009235"/>
</source>
</evidence>
<evidence key="20" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15102711"/>
</source>
</evidence>
<evidence key="21" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15930137"/>
</source>
</evidence>
<evidence key="22" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16021330"/>
</source>
</evidence>
<evidence key="23" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16901901"/>
</source>
</evidence>
<evidence key="24" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16971387"/>
</source>
</evidence>
<evidence key="25" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="17908927"/>
</source>
</evidence>
<evidence key="26" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="18070875"/>
</source>
</evidence>
<evidence key="27" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="18311786"/>
</source>
</evidence>
<evidence key="28" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="18617530"/>
</source>
</evidence>
<evidence key="29" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="19036738"/>
</source>
</evidence>
<evidence key="30" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="19542233"/>
</source>
</evidence>
<evidence key="31" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="20453062"/>
</source>
</evidence>
<evidence key="32" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="21728993"/>
</source>
</evidence>
<evidence key="33" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="22036712"/>
</source>
</evidence>
<evidence key="34" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="22961547"/>
</source>
</evidence>
<evidence key="35" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="23624058"/>
</source>
</evidence>
<evidence key="36" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="23922729"/>
</source>
</evidence>
<evidence key="37" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="25538239"/>
</source>
</evidence>
<evidence key="38" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="25544560"/>
</source>
</evidence>
<evidence key="39" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="26231210"/>
</source>
</evidence>
<evidence key="40" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9771710"/>
</source>
</evidence>
<evidence key="41" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9931343"/>
</source>
</evidence>
<evidence key="42" type="ECO:0000303">
<source>
<dbReference type="PubMed" id="11001928"/>
</source>
</evidence>
<evidence key="43" type="ECO:0000303">
<source>
<dbReference type="PubMed" id="11175283"/>
</source>
</evidence>
<evidence key="44" type="ECO:0000303">
<source>
<dbReference type="PubMed" id="11883934"/>
</source>
</evidence>
<evidence key="45" type="ECO:0000303">
<source>
<dbReference type="PubMed" id="14702039"/>
</source>
</evidence>
<evidence key="46" type="ECO:0000303">
<source>
<dbReference type="PubMed" id="15489334"/>
</source>
</evidence>
<evidence key="47" type="ECO:0000303">
<source>
<dbReference type="PubMed" id="16901901"/>
</source>
</evidence>
<evidence key="48" type="ECO:0000303">
<source>
<dbReference type="PubMed" id="22036712"/>
</source>
</evidence>
<evidence key="49" type="ECO:0000303">
<source>
<dbReference type="PubMed" id="25538239"/>
</source>
</evidence>
<evidence key="50" type="ECO:0000303">
<source>
<dbReference type="PubMed" id="25544560"/>
</source>
</evidence>
<evidence key="51" type="ECO:0000303">
<source>
<dbReference type="PubMed" id="9771710"/>
</source>
</evidence>
<evidence key="52" type="ECO:0000303">
<source>
<dbReference type="PubMed" id="9931343"/>
</source>
</evidence>
<evidence key="53" type="ECO:0000303">
<source ref="4"/>
</evidence>
<evidence key="54" type="ECO:0000305"/>
<evidence key="55" type="ECO:0000305">
<source>
<dbReference type="PubMed" id="11001928"/>
</source>
</evidence>
<evidence key="56" type="ECO:0000305">
<source>
<dbReference type="PubMed" id="11220751"/>
</source>
</evidence>
<evidence key="57" type="ECO:0000305">
<source>
<dbReference type="PubMed" id="11739371"/>
</source>
</evidence>
<evidence key="58" type="ECO:0000305">
<source>
<dbReference type="PubMed" id="14532330"/>
</source>
</evidence>
<evidence key="59" type="ECO:0000305">
<source>
<dbReference type="PubMed" id="22036712"/>
</source>
</evidence>
<evidence key="60" type="ECO:0000305">
<source>
<dbReference type="PubMed" id="25538239"/>
</source>
</evidence>
<evidence key="61" type="ECO:0000305">
<source>
<dbReference type="PubMed" id="25544560"/>
</source>
</evidence>
<evidence key="62" type="ECO:0000305">
<source>
<dbReference type="PubMed" id="26231210"/>
</source>
</evidence>
<sequence length="331" mass="37158" checksum="DD79F917262AB458" modified="2000-05-01" version="2">
MRFRFGVVVPPAVAGARPELLVVGSRPELGRWEPRGAVRLRPAGTAAGDGALALQEPGLW
LGEVELAAEEAAQDGAEPGRVDTFWYKFLKREPGGELSWEGNGPHHDRCCTYNENNLVDG
VYCLPIGHWIEATGHTNEMKHTTDFYFNIAGHQAMHYSRILPNIWLGSCPRQVEHVTIKL
KHELGITAVMNFQTEWDIVQNSSGCNRYPEPMTPDTMIKLYREEGLAYIWMPTPDMSTEG
RVQMLPQAVCLLHALLEKGHIVYVHCNAGVGRSTAAVCGWLQYVMGWNLRKVQYFLMAKR
PAVYIDEEALARAQEDFFQKFGKVRSSVCSL
</sequence>
</entry>
<copyright>
Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
Distributed under the Creative Commons Attribution-NoDerivs License
</copyright>
</uniprot>